127 related articles for article (PubMed ID: 17852444)
1. Myelodysplastic syndrome associated with chronic valproic acid therapy: a case report and review of the literature.
Allan RW
Hematology; 2007 Dec; 12(6):493-6. PubMed ID: 17852444
[TBL] [Abstract][Full Text] [Related]
2. Valproate-associated dysmyelopoiesis in elderly patients.
So CC; Wong KF
Am J Clin Pathol; 2002 Aug; 118(2):225-8. PubMed ID: 12162682
[TBL] [Abstract][Full Text] [Related]
3. Severe hematologic toxicity of valproic acid. A report of four patients.
Ganick DJ; Sunder T; Finley JL
Am J Pediatr Hematol Oncol; 1990; 12(1):80-5. PubMed ID: 2106802
[TBL] [Abstract][Full Text] [Related]
4. Acute leukemia associated with valproic acid treatment: a novel mechanism for leukemogenesis?
Coyle TE; Bair AK; Stein C; Vajpayee N; Mehdi S; Wright J
Am J Hematol; 2005 Apr; 78(4):256-60. PubMed ID: 15795916
[TBL] [Abstract][Full Text] [Related]
5. Dose-related thrombocytopenia and macrocytic anemia associated with valproate use in bipolar disorder.
Fawcett RG
J Clin Psychiatry; 1997 Mar; 58(3):125. PubMed ID: 9108818
[No Abstract] [Full Text] [Related]
6. Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia.
Kuendgen A; Knipp S; Fox F; Strupp C; Hildebrandt B; Steidl C; Germing U; Haas R; Gattermann N
Ann Hematol; 2005 Dec; 84 Suppl 1():61-6. PubMed ID: 16270213
[TBL] [Abstract][Full Text] [Related]
7. Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid.
Pilatrino C; Cilloni D; Messa E; Morotti A; Giugliano E; Pautasso M; Familiari U; Cappia S; Pelicci PG; Lo Coco F; Saglio G; Guerrasio A
Cancer; 2005 Jul; 104(1):101-9. PubMed ID: 15895376
[TBL] [Abstract][Full Text] [Related]
8. Combining DNA methyltransferase and histone deacetylase inhibition to treat acute myeloid leukemia/myelodysplastic syndrome: achievements and challenges.
Lübbert M; Kuendgen A
Cancer; 2015 Feb; 121(4):498-501. PubMed ID: 25336205
[No Abstract] [Full Text] [Related]
9. Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial.
Candelaria M; Herrera A; Labardini J; González-Fierro A; Trejo-Becerril C; Taja-Chayeb L; Pérez-Cárdenas E; de la Cruz-Hernández E; Arias-Bofill D; Vidal S; Cervera E; Dueñas-Gonzalez A
Ann Hematol; 2011 Apr; 90(4):379-87. PubMed ID: 20922525
[TBL] [Abstract][Full Text] [Related]
10. Intraoperative defect in haemostasis in a child receiving valproic acid.
Tetzlaff JE
Can J Anaesth; 1991 Mar; 38(2):222-4. PubMed ID: 2021993
[TBL] [Abstract][Full Text] [Related]
11. Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia.
Bug G; Ritter M; Wassmann B; Schoch C; Heinzel T; Schwarz K; Romanski A; Kramer OH; Kampfmann M; Hoelzer D; Neubauer A; Ruthardt M; Ottmann OG
Cancer; 2005 Dec; 104(12):2717-25. PubMed ID: 16294345
[TBL] [Abstract][Full Text] [Related]
12. Reversible dementia and gait disturbance after prolonged use of valproic acid.
Evans MD; Shinar R; Yaari R
Seizure; 2011 Jul; 20(6):509-11. PubMed ID: 21435910
[TBL] [Abstract][Full Text] [Related]
13. More is better: combination therapies for myelodysplastic syndromes.
Ornstein MC; Mukherjee S; Sekeres MA
Best Pract Res Clin Haematol; 2015 Mar; 28(1):22-31. PubMed ID: 25659727
[TBL] [Abstract][Full Text] [Related]
14. Haematological disturbances during long-term valproate therapy.
Brichard B; Vermylen C; Scheiff JM; Ninane J; Cornu G
Eur J Pediatr; 1994 May; 153(5):378-80. PubMed ID: 8033931
[TBL] [Abstract][Full Text] [Related]
15. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia.
Kuendgen A; Schmid M; Schlenk R; Knipp S; Hildebrandt B; Steidl C; Germing U; Haas R; Dohner H; Gattermann N
Cancer; 2006 Jan; 106(1):112-9. PubMed ID: 16323176
[TBL] [Abstract][Full Text] [Related]
16. Translocation-positive acute myeloid leukemia associated with valproic acid therapy.
Williams DC; Massey GV; Russell EC; Riley RS; Ben-Ezra J
Pediatr Blood Cancer; 2008 Mar; 50(3):641-3. PubMed ID: 17262798
[TBL] [Abstract][Full Text] [Related]
17. [Acute pancreatitis induced by valproic acid].
Jomli R; Nacef F; Douki S
Encephale; 2013 Sep; 39(4):292-5. PubMed ID: 23541917
[TBL] [Abstract][Full Text] [Related]
18. Current status of epigenetic treatment in myelodysplastic syndromes.
Kuendgen A; Lübbert M
Ann Hematol; 2008 Aug; 87(8):601-11. PubMed ID: 18392623
[TBL] [Abstract][Full Text] [Related]
19. Trisomy 14 in myelodysplastic syndromes: report of two cases and review of the literature.
Vasef MA; Murata-Collins JL; Alsabeh R; Medeiros LJ
Arch Pathol Lab Med; 1998 Jan; 122(1):77-83. PubMed ID: 9448022
[TBL] [Abstract][Full Text] [Related]
20. Valproic acid for the treatment of myeloid malignancies.
Kuendgen A; Gattermann N
Cancer; 2007 Sep; 110(5):943-54. PubMed ID: 17647267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
